Mycobacterium avium vaccine - Antigenics

Drug Profile

Mycobacterium avium vaccine - Antigenics

Latest Information Update: 19 Aug 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antigenics
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Mycobacterium avium complex infections

Most Recent Events

  • 19 Aug 1999 Discontinued-Preclinical for Mycobacterium avium complex infections in USA (Unknown route)
  • 20 Jul 1998 No-Development-Reported for Mycobacterium avium complex infections in USA (Unknown route)
  • 03 Aug 1995 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top